stock-detail (MEIP)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer

4/3/2017 12:00 pm

[PR Newswire] - SAN DIEGO, April 3, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the appointment of Brian Drazba as Chief Financial Officer. Mr. Drazba joins the Company with more than 25 years of financial management experience in the healthcare industry, most recently as Chief Financial Officer of Heron Therapeutics, Inc., a commercial-stage biotechnology company.

MEI Pharma to Present at Needham Healthcare Conference

3/28/2017 01:00 pm

[PR Newswire] - SAN DIEGO, March 28, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Needham Healthcare Conference on Tuesday, April 4, 2017 at 4:20 p.m. Eastern time from the Westin New York Grand Central. MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.

MEI Pharma to Present at Oppenheimer Healthcare Conference

3/14/2017 01:00 pm

[PR Newswire] - SAN DIEGO, March 14, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer Healthcare Conference on Tuesday, March 21, 2017 at 9:10 a.m. Eastern time from the Westin New York Grand Central. MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.

MEI PHARMA, INC. Financials

2/11/2017 06:00 pm

Post Earnings Coverage as Summit Therapeutics Q3 Net Loss Narrowed; Entered into Agreement with Sarepta

12/27/2016 01:01 pm

[Accesswire] - Upcoming AWS Coverage on MEI Pharma Post-Earnings Results LONDON, UK / ACCESSWIRE / December 27, 2016 / Active Wall St. announces its post-earnings coverage on Summit Therapeutics PLC (NASDAQ: SMMT). The ...

Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

12/5/2016 01:00 pm

[PR Newswire] - LUGANO, Switzerland, and SAN DIEGO, Dec. 5, 2016 /PRNewswire/ -- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced final results from a Phase 2 clinical study of the investigational drug candidate Pracinostat and azacitidine in elderly patients with acute myeloid leukemia (AML) who were not eligible for induction chemotherapy, including evidence of prolongation of survival in the overall population and across a number of patient subgroups. In an oral presentation at the American Society of Hematology (ASH) Annual Meeting on Saturday, Dr. Guillermo Garcia-Manero, MD Anderson Cancer Center, principal investigator of the study, reported a median overall survival of 19.1 (95%CI: 10.7-26.5) months, one-year survival of 62% and a complete response (CR) rate of 42%.

MEI Pharma to Host Annual Meeting of Stockholders

11/17/2016 02:00 pm

[PR Newswire] - SAN DIEGO, Nov. 17, 2016 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Pacific time on Thursday, December 1, 2016, at the Company's headquarters, located at 11975 El Camino Real, Suite 101, San Diego, CA 92130. Stockholders of record at the close of business on October 5, 2016 are entitled to receive notice of and vote at the Annual Meeting. MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.

MEI Pharma Reports First Quarter Fiscal Year 2017 Results

11/9/2016 01:03 pm

[PR Newswire] - SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today reported results for its first quarter ...

MEI Pharma Reports First Quarter Fiscal Year 2017 Results

11/9/2016 01:03 pm

[at noodls] - SAN DIEGO, Nov. 9, 2016/PRNewswire / -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today reported results for its first quarter ...

MEI Pharma to Present at Stifel Healthcare Conference

11/7/2016 02:00 pm

[PR Newswire] - SAN DIEGO, Nov. 7, 2016 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference on Tuesday, November 15, 2016 at 3:45 p.m. Eastern time from the Lotte New York Palace Hotel. MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.

Blog Coverage MEI Pharma and Helsinn Group Announced Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia

11/4/2016 12:01 pm

[Accesswire] - Upcoming AWS Coverage on Depomed Post-Earnings Results LONDON, UK / ACCESSWIRE / November 4, 2016 / Active Wall St. blog coverage looks at the headline from MEI Pharma, Inc. (NASDAQ: MEIP ) and Swiss pharmaceutical ...

Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting

11/3/2016 01:00 pm

[PR Newswire] - LUGANO, Switzerland and SAN DIEGO, Nov. 3, 2016 /PRNewswire/ -- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that long-term survival and response data from a Phase II clinical study of Pracinostat and azacitidine in older patients with acute myeloid leukemia have been selected for oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting in San Diego on December 3-6, 2016. An abstract of the presentation was published today on the ASH website at www.hematology.org.